全文获取类型
收费全文 | 317篇 |
免费 | 47篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 12篇 |
妇产科学 | 10篇 |
基础医学 | 47篇 |
口腔科学 | 1篇 |
临床医学 | 42篇 |
内科学 | 71篇 |
皮肤病学 | 4篇 |
神经病学 | 8篇 |
特种医学 | 13篇 |
外科学 | 68篇 |
综合类 | 2篇 |
预防医学 | 30篇 |
药学 | 17篇 |
肿瘤学 | 38篇 |
出版年
2022年 | 3篇 |
2021年 | 4篇 |
2019年 | 4篇 |
2018年 | 7篇 |
2017年 | 4篇 |
2016年 | 7篇 |
2015年 | 6篇 |
2014年 | 8篇 |
2013年 | 11篇 |
2012年 | 14篇 |
2011年 | 4篇 |
2010年 | 8篇 |
2009年 | 9篇 |
2008年 | 9篇 |
2007年 | 11篇 |
2006年 | 14篇 |
2005年 | 18篇 |
2004年 | 15篇 |
2003年 | 9篇 |
2002年 | 17篇 |
2001年 | 19篇 |
2000年 | 18篇 |
1999年 | 14篇 |
1998年 | 7篇 |
1997年 | 2篇 |
1996年 | 6篇 |
1995年 | 3篇 |
1993年 | 2篇 |
1992年 | 6篇 |
1991年 | 10篇 |
1990年 | 10篇 |
1989年 | 6篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 4篇 |
1973年 | 5篇 |
1972年 | 3篇 |
1971年 | 5篇 |
1970年 | 6篇 |
1968年 | 2篇 |
1967年 | 5篇 |
1965年 | 3篇 |
1961年 | 2篇 |
1911年 | 1篇 |
排序方式: 共有364条查询结果,搜索用时 15 毫秒
1.
Cobb's collar or Moormann's ring is a stricture of the bulbar urethra which is largely unrecognised but has considerable relevance urologically as the site of congenital or post-instrumental strictures. The history, anatomy, embryology and surgical importance are reported. 相似文献
2.
HRAS1-selected, chromosome-mediated transformants vary in phenotype in vitro and tumorigenic potential in vivo 总被引:1,自引:0,他引:1
D J Porteous J E Morten M E Foster G Cranston E Weir-Thompson A Busuttil C J Bobstock C M Steel 《International journal of cancer. Journal international du cancer》1986,38(4):603-612
Transfection of mouse C127 cells with mitotic chromosomes isolated from a human EJ bladder carcinoma cell line gave rise, at high frequency, to foci of transformed cells. Independent, HRAS1-selected chromosome-mediated transformants displayed distinctive cellular morphologies in monolayer culture and colony-forming abilities in low-melting-point agarose. Subcutaneous inoculation of neonatally thymectomized, Ara-C-protected, total-body-irradiated CBA mice was used to compare the tumorigenic potential of each transformant. Significant quantitative and qualitative differences in tumorigenicity were found between transformants which correlated with differences in malignant phenotype observed in vitro. The sensitivity of the tumorigenicity assay is such that rare transformation events can be selected directly in vivo. 相似文献
3.
O'Shea S Chrystie I Cranston R Mullen J Corbett K Murphy G Parry JV De Ruiter A Banatvala J 《Journal of medical virology》2000,61(2):187-194
During routine monitoring of human immunodeficiency virus (HIV) viral load, two problems arose. First, a number of patients, the majority being African, were found to have low viral loads by the Chiron branched-chain DNA assay in conjunction with low CD4(+) cell numbers. In order to determine whether this was due to failure of the branched-chain DNA assay to detect non-B subtypes of HIV, selected samples were subtyped and HIV RNA quantified by branched-chain DNA, NASBA, and the Roche Monitor RT-PCR assay. Twenty-eight (97%) of 29 Africans were infected with a non-B subtype of HIV and 15 (93.7%) of 16 non-Africans with subtype B. Twenty-three samples had a low viral load by branched-chain DNA, which was confirmed by the NASBA and RT-PCR assays. All three assays detected B and non-B subtypes with similar efficiency; NASBA failed to detect HIV RNA in a small number of non-B samples. Discrepancies between viral load and CD4(+) cell numbers did not appear therefore to be related to subtype. Second, while quantification of HIV RNA was being conducted using version 2 of the branched-chain DNA assay (lower detection limit 500 HIV RNA copies/ml) the manufacturers had developed a more sensitive assay and a comparative evaluation was therefore conducted. In approximately 30% of samples the viral load was up to 10 times higher with the more sensitive assay. These experiences emphasise the importance of close collaboration between the clinic and the laboratory. 相似文献
4.
5.
6.
Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates 总被引:20,自引:0,他引:20
Crew JP O'Brien T Bicknell R Fuggle S Cranston D Harris AL 《The Journal of urology》1999,161(3):799-804
PURPOSE: Vascular endothelial growth factor (VEGF) is a principal growth factor mediating tumor angiogenesis. The high expression of VEGF within bladder tumors is associated with a poor prognosis. We quantified urinary VEGF and determined its potential as a prognostic marker in bladder cancer. MATERIALS AND METHODS: VEGF was measured by enzyme-linked immunosorbent assay in the urine of 261 patients, including 153 undergoing cystoscopic surveillance for bladder cancer and 108 with another advanced malignancy or a benign urological condition. The source of urinary VEGF was studied through its quantification in bladder tumors and normal bladders. RESULTS: Urinary VEGF was higher in patients undergoing cystoscopic surveillance for bladder cancer than in those with an advanced nonbladder malignancy (p <0.0001) or a benign urological condition (p = 0.004). The highest levels were noted in patients with bladder cancer compared to those with clear cystoscopy (p <0.0001). In 26 cases the correlation between VEGF protein levels in bladder cancer and urine (r = 0.67, p = 0.003) suggested that the tumor is a source of urinary VEGF. Increased VEGF protein in normal urothelium in 22 patients with bladder cancer compared to that in 7 cadaveric organ donors (p = 0.002) indicates that urinary VEGF may also be derived from nonmalignant urothelium. In 61 cases we established a correlation between urinary VEGF and stage T1 or less superficial bladder tumor recurrence rates (r = 0.45, p <0.0001). CONCLUSIONS: Our study demonstrates that VEGF is high in the urine of patients with bladder cancer and it correlates with tumor recurrence rates. VEGF is implicated in the pathogenesis of bladder cancer recurrence. Its quantification may provide a valuable noninvasive marker for the early detection of bladder tumor recurrence as well as a therapy target. 相似文献
7.
Aya El Helali Ruth Plummer Gordon C. Jayson Vicky M. Coyle Yvette Drew Nerissa Mescallado Noor Harris Andrew R. Clamp Janine McCann Helen Swaisland Richard D. Kennedy Aaron N. Cranston Richard H. Wilson 《British journal of cancer》2022,127(1):92
Background We aimed to assess the safety, tolerability and pharmacokinetics of a novel anti-angiogenic peptide.Methods We used an open-label, multicentre, dose-escalation Phase I trial design in patients with solid tumours. ALM201 was administered subcutaneously once daily for 5 days every week in unselected patients with solid tumours.Results Twenty (8 male, 12 female) patients with various solid tumours were treated (18 evaluable for toxicity) over eight planned dose levels (10–300 mg). ALM201 was well-tolerated at all dose levels without CTCAE grade 4 toxicities. Adverse events were predominantly grades 1–2, most commonly, localised injection-site reactions (44.4%), vomiting (11%), fatigue (16.7%), arthralgia (5.6%) and headache (11%). Thrombosis occurred in two patients at the 100 mg and 10 mg dose levels. The MTD was not reached, and a recommended Phase II dose (RP2D) based on feasibility was declared. Plasma exposure increased with dose (less than dose-proportional at the two highest dose levels). No peptide accumulation was evident. The median treatment duration was 11.1 (range 3–18) weeks. Four of 18 evaluable patients (22%) had stable disease.Conclusions Doses up to 300 mg of ALM201 subcutaneously are feasible and well-tolerated. Further investigation of this agent in selected tumour types/settings would benefit from patient-selection biomarkers.Subject terms: Drug development, Drug safety 相似文献
8.
Humphries SE Cranston T Allen M Middleton-Price H Fernandez MC Senior V Hawe E Iversen A Wray R Crook MA Wierzbicki AS 《Journal of molecular medicine (Berlin, Germany)》2006,84(3):203-214
As part of a randomised trial [Genetic Risk Assessment for Familial Hypercholesterolaemia (FH) Trial] of the psychological
consequences of DNA-based and non-DNA-based diagnosis of FH, 338 probands with a clinical diagnosis of FH (46% with tendon
xanthomas) were recruited. In the DNA-based testing arm (245 probands), using single-strand conformation polymorphism of all
exons of the low-density lipoprotein receptor (LDLR) gene, 48 different pathogenic mutations were found in 62 probands (25%), while 7 (2.9%) of the patients had the R3500Q mutation
in the apolipoprotein B (APOB) gene. Compared to those with no detected mutation, mean untreated cholesterol levels in those with the APOB mutation were similar, while in those with an LDLR mutation levels were significantly higher (None=9.15±1.62 vs LDLR=9.13±1.16 vs APOB=10.26±2.07 mmol/l p<0.001, respectively). Thirty seven percent of the detected mutations were in exon 3/4 of LDLR, and this group had significantly higher untreated cholesterol than those with other LDLR mutations (11.71±2.39 mmol/l vs 9.88±2.44 mmol/l, p=0.03), and more evidence of coronary disease compared to those with other LDLR or APOB mutations (36 vs 13% p=0.04). Of the probands with a detected mutation, 54 first-degree relatives were identified, of whom 27 (50%) had a mutation.
Of these, 18 had untreated cholesterol above the 95th percentile for their age and gender, but there was overlap with levels
in the non-carrier relatives such that 12% of subjects would have been incorrectly diagnosed on lipid levels alone. In the
non-DNA-based testing arm (82 probands) only 19 of the 74 relatives identified had untreated cholesterol above the 95th percentile
for their age and gender, which was significantly lower (p<0.0005) than the 50% expected for monogenic inheritance. These data confirm the genetic heterogeneity of LDLR mutations in the UK and the deleterious effect of mutations in exon 3 or 4 of LDLR on receptor function, lipids and severity of coronary heart disease. In patients with a clinical diagnosis of FH but no detectable
mutation, there is weaker evidence for a monogenic cause compared with relatives of probands with LDLR mutations. This supports the usefulness of DNA testing to confirm diagnosis of FH for the treatment of hyperlipidaemia and
for further cascade screening. 相似文献
9.
Heather A. Pines Pamina M. Gorbach Robert E. Weiss Kristen Hess Ryan Murphy Terry Saunders Joelle Brown Peter A. Anton Ross D. Cranston 《AIDS and behavior》2013,17(3):1002-1015
We assessed the acceptability of three of over-the-counter products representative of potential rectal microbicide (RM) delivery systems. From 2009 to 2010, 117 HIV-uninfected males (79 %) and females (21 %) who engage in receptive anal intercourse participated in a 6-week randomized crossover acceptability trial. Participants received each of three products (enema, lubricant-filled applicator, suppository) every 2 weeks in a randomized sequence. CASI and T-ACASI scales assessed product acceptability via Likert responses. Factor analysis was used to identify underlying factors measured by each scale. Random effects models were fit to examine age and gender effects on product acceptability. Three underlying factors were identified: Satisfaction with Product Use, Sexual Pleasure, and Ease of Product Use. For acceptability, the applicator ranked highest; however, differences between product acceptability scores were greatest among females and younger participants. These findings indicate that RM delivery systems impact their acceptability and should be considered early in RM development to enhance potential use. 相似文献
10.
Bauermeister José A. Tingler Ryan C. Dominguez Clara Dunne Eileen F. Hoesley Craig Ho Ken Johnson Sherri Lucas Jonathan Macagna Nicole Brown Elizabeth Gundacker Holly Peda Melissa Jacobson Cindy E. Kramzer Lindsay Singh Devika Dezzutti Charlene S. Ayudhya Ratiya Pamela Kunjara Na Marzinke Mark A. Piper Jeanna Devlin Bríd Nuttall Jeremy McGowan Ian Hendrix Craig W. Cranston Ross D. 《AIDS and behavior》2022,26(5):1333-1346
AIDS and Behavior - This study describes the acceptability of a rectal microbicide gel formulation using dapivirine (DPV) among men and women from two countries (United States and Thailand)... 相似文献